
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progressi... Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States. 詳細を表示
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.215 | 2.99026425591 | 7.19 | 7.93 | 6.79 | 1320884 | 7.50011759 | CS |
4 | -1.015 | -12.054631829 | 8.42 | 8.53 | 6.79 | 1141042 | 7.69775173 | CS |
12 | -1.825 | -19.7724810401 | 9.23 | 9.33 | 6.79 | 1638787 | 8.16911043 | CS |
26 | -12.765 | -63.2870599901 | 20.17 | 21.4 | 6.79 | 1528487 | 10.64847594 | CS |
52 | -14.945 | -66.8680089485 | 22.35 | 23.48 | 6.79 | 1111369 | 13.80360127 | CS |
156 | -8.805 | -54.3183220234 | 16.21 | 24.17 | 6.79 | 958719 | 13.90870923 | CS |
260 | -1.445 | -16.3276836158 | 8.85 | 42.82 | 6.34 | 855439 | 16.68895649 | CS |
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約